Mr. Garen Sarafian reports

BAUSCH HEALTH ANNOUNCES FULL REDEMPTION OF 8.500% SENIOR NOTES DUE 2027

Bausch Health Companies Inc.'s subsidiary, Bausch Health Americas Inc., will issue an irrevocable notice of redemption dated as of Oct. 29, 2026, pursuant to which it will redeem approximately $643-million of aggregate principal amount of its outstanding 8.500 per cent senior notes due 2027, Cusip No. 91911X AW 4 and Cusip No. U9098V AP 7, using cash on hand. The redemption date is Nov. 30, 2026. The notice of redemption will be issued to the record holders of such notes. Nothing contained herein shall constitute a notice of redemption of the notes. Payment of the redemption price and surrender of the notes for redemption will be made through the facilities of the Depository Trust Company in accordance with the applicable procedures of the Depository Trust Company. The name and address of the U.S. paying agent are as follows: The Bank of New York Mellon, 240 Greenwich St., Floor 7E, New York, N.Y., 10286; attention: corporate trust administration. In connection with the redemption, the indenture pursuant to which the notes were issued will be terminated.

About Bausch Health Companies Inc.

Bausch Health is a global, diversified pharmaceutical company enriching lives through its relentless drive to deliver better health care outcomes. The company develops, manufactures and markets a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through its controlling interest in Bausch + Lomb. The company's ambition is to be a globally integrated health care company, trusted and valued by patients, HCPs, employees and investors.

We seek Safe Harbor.